NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances-Reference-Cited by-同舟云学术

NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances

Published:2018-11 Issue:11 Volume:113 Page:1649-1659
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:

Author:

Noureddin Mazen,Vipani Aarshi,Bresee Catherine,Todo Tsuyoshi,Kim Irene K.,Alkhouri Naim,Setiawan Veronica Wendy,Tran Tram,Ayoub Walid S.,Lu Shelly C.,Klein Andrew S.,Sundaram Vinay,Nissen Nicholas N.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Link

http://www.nature.com/articles/s41395-018-0088-6.pdf

Reference42 articles.

1. OPTNSRTR 2015 annual data report: liver.;Kim;Am J Transplant,2017

2. Hepatocellular carcinoma is the most common indication for liver transplantation and placement on the waitlist in the United States.;Yang;Clin Gastroenterol Hepatol,2017

3. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.;Flemming;Hepatology,2017

4. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation.;Goldberg;Gastroenterology,2017

5. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.;Wong;Gastroenterology,2015

Cited by 437 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gut microbiota–NLRP3 inflammasome crosstalk in metabolic dysfunction-associated steatotic liver disease;Clinics and Research in Hepatology and Gastroenterology;2024-10

2. Low muscle quality index is associated with increased risk of advanced fibrosis in adult patients with nonalcoholic fatty liver disease: NHANES 2011–2014;Scientific Reports;2024-08-27

3. Cardiac abnormalities pre- and post-liver transplantation for metabolic dysfunction-associated steatohepatitis – Evidence and special considerations;Journal of Liver Transplantation;2024-08

4. A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease;Diabetes & Metabolism Journal;2024-07-31

5. The effect of vitamin E and docosahexaenoic acid ethyl ester on Metabolic Dysfunction‐Associated steatotic Liver Disease (MASLD)—A randomised, double‐blind, placebo‐controlled, parallel‐group clinical trial (PUVENAFLD);Alimentary Pharmacology & Therapeutics;2024-07-12